Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASPEN: Zanubrutinib vs Ibrutinib in Waldenström's Macroglobulinemia
NCT03053440Phase 3Completed
- Sponsor
- BeiGene
- Start
- Jan 2017
- Primary completion
- Jun 2022
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 12
01
Overview
A Phase 3 trial of zanubrutinib in Waldenström's macroglobulinemia (WM), sponsored by BeiGene. Started Jan 2017; status: completed.
02
Drugs
zanubrutinib
03
Conditions
Waldenström's macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT03053440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03053440.